A Multicenter, Open-Label, Single- and Multiple-Dose, Dose-Finding Study to Assess the Effects of Obeticholic Acid in Pediatric Subjects with Biliary Atresia

Trial Profile

A Multicenter, Open-Label, Single- and Multiple-Dose, Dose-Finding Study to Assess the Effects of Obeticholic Acid in Pediatric Subjects with Biliary Atresia

Recruiting
Phase of Trial: Phase II

Latest Information Update: 11 Jun 2018

At a glance

  • Drugs Obeticholic acid (Primary)
  • Indications Biliary atresia
  • Focus Adverse reactions; Pharmacokinetics
  • Acronyms CARE
  • Sponsors Intercept Pharmaceuticals
  • Most Recent Events

    • 08 Jun 2018 Planned End Date changed from 1 Mar 2017 to 29 Jun 2020.
    • 08 Jun 2018 Planned number of patients changed from 60 to 72.
    • 23 Mar 2018 According to an Intercept Pharmaceuticals media release, results from this study will be present at the International Liver Congress 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top